References
- Dib-Hajj SD , YangY , BlackJA , WaxmanSG . The Na(v)1.7 sodium channel: from molecule to man . Nat. Rev. Neurosci.14 ( 1 ), 49 – 62 ( 2013 ).
- Fertleman CR , BakerMD , ParkerKAet al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes . Neuron52 ( 5 ), 767 – 774 ( 2006 ).
- Dib-Hajj SD , EstacionM , JareckiBWet al. Paroxysmal extreme pain disorder M1627K mutation in human Nav1.7 renders DRG neurons hyperexcitable . Mol. Pain4 , 37 ( 2008 ).
- Suter MR , BhuiyanZA , LaedermannCJet al. p.L1612p, a novel voltage-gated sodium channel Nav1.7 mutation inducing a cold sensitive paroxysmal extreme pain disorder . Anesthesiology122 ( 2 ), 414 – 423 ( 2015 ).
- Fertleman CR , FerrieCD , AicardiJet al. Paroxysmal extreme pain disorder (previously familial rectal pain syndrome) . Neurology69 ( 6 ), 586 – 595 ( 2007 ).
- Estacion M , Dib-HajjSD , BenkePJet al. Nav1.7 gain-of-function mutations as a continuum: A1632e displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders . J. Neurosci.28 ( 43 ), 11079 – 11088 ( 2008 ).
- Imai N , MiyakeN , SaitoYet al. Short-lasting unilateral neuralgiform headache attacks with ispilateral facial flushing is a new variant of paroxysmal extreme pain disorder . J. Headache Pain16 ( 1 ), 519 ( 2015 ).
- Waxman SG , MerkiesIS , GerritsMMet al. Sodium channel genes in pain-related disorders: phenotype-genotype associations and recommendations for clinical use . Lancet Neurol.13 ( 11 ), 1152 – 1160 ( 2014 ).
- Von Hehn CA , BaronR , WoolfCJ . Deconstructing the neuropathic pain phenotype to reveal neural mechanisms . Neuron73 ( 4 ), 638 – 652 ( 2012 ).
- Rush AM , Dib-HajjSD , LiuS , CumminsTR , BlackJA , WaxmanSG . A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons . Proc. Natl Acad. Sci. USA103 ( 21 ), 8245 – 8250 ( 2006 ).
- Schmalhofer WA , CalhounJ , BurrowsRet al. ProTx-II, a selective inhibitor of Nav1.7 sodium channels, blocks action potential propagation in nociceptors . Mol. Pharmacol.74 ( 5 ), 1476 – 1484 ( 2008 ).
- Kessner S , ForkmannK , RitterC , WiechK , PlonerM , BingelU . The effect of treatment history on therapeutic outcome: psychological and neurobiological underpinnings . PLoS ONE9 ( 9 ), e109014 ( 2014 ).
- Finnerup NB , AttalN , HaroutounianSet al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis . Lancet Neurol.14 ( 2 ), 162 – 173 ( 2015 ).
- Moulin D , BoulangerA , ClarkAJet al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society . Pain Res. Manag.19 ( 6 ), 328 – 335 ( 2014 ).
- Choi JS , BoraleviF , BrissaudOet al. Paroxysmal extreme pain disorder: a molecular lesion of peripheral neurons . Nat. Rev. Neurol.7 ( 1 ), 51 – 55 ( 2011 ).
- Choi JS , ZhangL , Dib-HajjSDet al. Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off . Exp. Neurol.216 ( 2 ), 383 – 389 ( 2009 ).
- Suter MR , KirschmannG , LaedermannCJ , AbrielH , DecosterdI . Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state . Anesthesiology118 ( 1 ), 160 – 172 ( 2013 ).
- Fischer TZ , GilmoreES , EstacionMet al. A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia . Ann. Neurol.65 ( 6 ), 733 – 741 ( 2009 ).
- Yang Y , Dib-HajjSD , ZhangJet al. Structural modelling and mutant cycle analysis predict pharmacoresponsiveness of a Na(v)1.7 mutant channel . Nat. Commun.3 , 1186 ( 2012 ).
- George AL Jr . Lessons learned from genetic testing for channelopathies . Lancet Neurol.13 ( 11 ), 1068 – 1070 ( 2014 ).